MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
Provided By GlobeNewswire
Last update: Jan 13, 2025
ROCKVILLE, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2024.
Read more at globenewswire.com
